Abstract: The present invention aims to provide a medicament capable of treating and/or preventing diseases associated with oxidative stress by inhibiting the protein-protein interaction between Keap1 and Nrf2 and activating Nrf2. The present invention relates to a compound represented by the following formula (1): wherein each symbol is as described in the DESCRIPTION, or a pharmaceutically acceptable salt thereof. In addition, the present invention also relates to a medicament containing the aforementioned compound, for the prophylaxis and/or treatment of diseases involving oxidative stress selected from the group consisting of chronic kidney disease, non-alcoholic steatohepatitis, chronic obstructive pulmonary disease, radiation skin disorder, radiation mucosal disorder, cardiac failure, pulmonary arterial hypertension, Parkinson's disease, Friedreich's ataxia, multiple sclerosis, age-related macular degeneration, retinitis pigmentosa and glaucoma.

Abstract: [Problem] To deal with interference in cases where a plurality of business operators perform testing at the same time at different MEG levels. [Solution] A network device 2 includes a frame distinguishing unit 22a that, upon receiving a start instruction for a test from a control device 3, monitors whether or not an OAM frame of a preceding test of a different level from a MEG level of an own device has arrived at the own device, for a predetermined period, and a CPU 24 that, if the frame distinguishing unit 22a detects arrival of the OAM frame, and determination is made that its own test will affect the preceding test, notifies the result of the detection and determination.

Abstract: [Problem] To deal with interference in cases where a plurality of business operators perform testing at the same time at different MEG levels. [Solution] A network device 2 includes a frame distinguishing unit 22a that, upon receiving a start instruction for a test from a control device 3, monitors whether or not an OAM frame of a preceding test of a different level from a MEG level of an own device has arrived at the own device, for a predetermined period, and a CPU 24 that, if the frame distinguishing unit 22a detects arrival of the OAM frame, and determination is made that its own test will affect the preceding test, notifies the result of the detection and determination.

Abstract: An owner concludes with a facility maintenance company a contract for maintenance of electric facilities and an operation control monitor device installed in a building of the owner. The electric facility manufacturer gives the company permission to access the device from a terminal through the Internet as a communication network. The company receives continuous monitor data items of the electric facilities collected by the device. The manufacturer accesses the device from a terminal through the network and also receives the continuous monitor data items of the electric facilities.

Abstract: An owner (10) concludes with a facility maintenance company (20) a contract for maintenance of electric facilities (11) and an operation control monitor device (12) installed in a building of the owner (10). The electric facility manufacture (30) gives the company (20) a permission to access the device (12) from a terminal (21) through the Internet (40) as a communication network. The company (20) receives continuous monitor data items of the electric facilities (11) collected by the device (20). The manufacture (30) accesses the device (12) form a terminal (31) through the network (40) and also receives the continuous monitor data items of the electric facilities (11).